Symtomax has made great progress in the last 2 years. The Company have completed the build of the greenhouses, fencing, security measures and dry facility, and received the final Infarmed license at the end of June 2021 for the cultivation, import and export of medical cannabis.
We started transplanting for our test crop from the greenhouse to the outdoor area in August 2021. This enabled us to use this test crop to choose our strongest genetics and to start incorporating our IPM program for 2022.
- Test the genetics in the microclimate in Beja
- Select the mother plants from which will be cloned, to cultivate stable flower which is required for the European medical cannabis market
- Understand the risk to the outdoor crop cycle to implement our IPM (Integrated Pest Management) program to ensure a smaller crop risk on larger cultivation cycles
- Complete full training on all members of staff and Quality Control protocols
We have now adjusted our operational plan to incorporate multiple rotation greenhouse crop cycles per year, which will provide monthly revenues from Quarter 2, and additionally this will allow Symtomax to produce a continual supply of flower all year round.
Going forward in 2022, we anticipate GACP flower ready for commercial sale from Quarter 2 onwards. We plan to start the construction of our EU-GMP production facility in Quarter1.